Intra-Cellular Therapies Other Current Assets

As of the most recent data (December 2024), ITCI shows a other current assets of $110M. That compares with $42M in the prior-year period — up 167.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's other current assets is now $110M (was $42M) — a 167.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

Tracking ITCI's other current assets over time shows whether Intra-Cellular Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $42M in the prior-year period — up 167.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $110M) with ownership activity and broader fundamentals.

Intra-Cellular Therapies's other current assets is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.